• Ti-Oss Syringe0.2-1.0mm
1 2

Chiyewon

Ti-Oss Bovine Cancellous Substitute Syringe

Ti-Oss Bovine Cancellous Substitute Syringe

$150.00
$150.00
Sale Sold out
Size
View full details
Ti-oss Cancellous Bone Substitute — Vial and Syringe
Chiyewon · Bone Graft

Ti-oss® Vial
Cancellous Bone Substitute

Ti-oss® is a 100% cancellous, BSE-free Australian bovine bone substitute manufactured by Chiyewon. Its multiporous structure and octacalcium phosphate (OCP)-coated surface are designed to maximise blood vessel ingrowth and support new bone formation, with published clinical and animal research showing performance comparable to a leading deproteinized bovine bone mineral. Available in Vial and Syringe formats across three particle size ranges.

100% BSE-Free Australian Bovine Bone 300–400 µm Macropore Structure High Yield Volume ❨Greater cc per gram❩
Clinical Insight

What clinicians are saying

Real-world feedback from implantologists and oral surgeons using Ti-oss® in their practices.

"For lateral window sinus grafts, what stands out with Ti-oss is how quickly the granules wet out — a few drops of blood or saline and the whole graft is saturated, so packing the cavity is fast and the material stays where I put it. The bone cores I've reviewed at re-entry show solid integration, consistent with the published pilot data."

Sinus Augmentation · Lateral Window Approach · Graft Handling

"I was cautious about moving away from a product I'd used for years, but the calvarial defect data showing comparable new bone formation to the industry standard DBBM at both 8 and 12 weeks gave me the confidence to trial Ti-oss in ridge preservation cases. Healing and graft incorporation have tracked with what I'd expect."

Ridge Preservation · Comparable Performance · Clinical Confidence
Resources

Clinical Documentation

Product Brochure Clinical Study: Sinus Augmentation Clinical Study: Calvarial Defect Model
Indications

When to use Ti-oss®

Ti-oss® covers the core range of bone grafting indications — from socket preservation at the time of extraction to maxillary sinus augmentation ahead of implant placement.

Sinus Augmentation — Lateral window approach to graft the maxillary sinus floor ahead of implant placement in the posterior maxilla.
Ridge Preservation — Socket grafting after extraction to maintain alveolar ridge dimensions ahead of future implant placement.
Horizontal & Vertical Ridge Augmentation — Reconstruction of deficient ridges, typically combined with a barrier membrane.
Peri-Implant Bone Defects — Grafting around dehiscence or fenestration defects identified at the time of implant placement.
Intrabony Periodontal Defects — Filling osseous defects as part of regenerative periodontal therapy.
Combination GBR Procedures — Used alongside a resorbable barrier membrane where guided bone regeneration is indicated.
Scientific Evidence

Test data & animal studies

Ti-oss® performance is supported by manufacturer testing across microstructural and animal studies, and by independent human biopsy cases.

① Multiporous Structure & Osteoconductive Surface

Multiporosity

Ti-oss multiporous macrostructure and pore size SEM comparison

Osteopromoting Factor

OCP crystals on Ti-oss surface, SEM 5000x and 50000x comparison
  • Made from 100% cancellous bone with no cortical portion — an innovative pulverising technique creates a multiporous structure designed to maximise blood vessel ingrowth
  • A pre-hydroxyapatite (Pre-HA) structure — octacalcium phosphate (OCP) crystals — is present on the particle surface, a feature associated with fast bone formation in manufacturer testing
  • Low-temperature processing preserves a natural, human bone-like surface topography while avoiding the vitrification associated with high-temperature manufacturing methods

② Multiporosity, Pore Size & Natural Topography — Animal Comparison

Ti-oss® vs. Competitor — Rabbit Tibia, 12 Weeks

Ti-oss versus competitor rabbit tibia histology comparison at 12 weeks
  • Angiogenesis supported by porosity design
  • Osteoblast movement supported by natural surface topography
  • Faster bone formation supported by the Pre-HA (OCP) surface structure
  • Source: Chiyewon Ti-oss® Product Brochure — rabbit tibia model, 12-week evaluation

③ Human Biopsy Results

3 Months & 4 Months Biopsy Findings

Combined histology of new bone and Ti-oss particles across 3 to 4 month human biopsy cases

Clinical human biopsy case reports from multiple implant centers

  • Across multiple independent clinical cases, biopsy specimens taken between 3 and 4 months after grafting showed new bone formation directly adjacent to Ti-oss® particles, with osteocyte lacunae visible within the newly formed bone
Available Formats

Ti-oss® Vial & Syringe — size options

Ti-oss® is supplied in three particle size ranges to suit different defect types, in both Vial and pre-filled Syringe formats.

Ti-oss® Syringe

SKU Weight / Volume Particle Size
S25-0210 0.25 g / 0.55 cc 0.2 – 1.0 mm
S05-0210 0.50 g / 1.10 cc 0.2 – 1.0 mm
S25-0512 0.25 g / 0.60 cc 0.5 – 1.2 mm
S05-0512 0.50 g / 1.20 cc 0.5 – 1.2 mm
S25-1217 0.25 g / 0.75 cc 1.2 – 1.7 mm
S05-1217 0.50 g / 1.50 cc 1.2 – 1.7 mm

Ti-oss® Vial

SKU Weight / Volume Particle Size
25-1217 0.25 g / 0.75 cc 1.2 – 1.7 mm
25-0512 0.25 g / 0.60 cc 0.5 – 1.2 mm
25-0210 0.25 g / 0.50 cc 0.2 – 1.0 mm
20-1217 2.00 g / 6.00 cc 1.2 – 1.7 mm
20-0512 2.00 g / 4.50 cc 0.5 – 1.2 mm
20-0210 2.00 g / 4.10 cc 0.2 – 1.0 mm
10-1217 1.00 g / 3.00 cc 1.2 – 1.7 mm
10-0512 1.00 g / 2.30 cc 0.5 – 1.2 mm
10-0210 1.00 g / 2.10 cc 0.2 – 1.0 mm
05-1217 0.50 g / 1.50 cc 1.2 – 1.7 mm
05-0512 0.50 g / 1.20 cc 0.5 – 1.2 mm
05-0210 0.50 g / 1.10 cc 0.2 – 1.0 mm
Specifications

Technical specifications

Device type Xenograft bone graft material — deproteinized bovine bone mineral (DBBM), octacalcium phosphate (OCP)-coated
Material origin 100% cancellous bovine bone, BSE-free certified, sourced from Australia
Surface treatment Octacalcium phosphate (OCP) coating — Pre-HA surface structure
Particle size ranges 0.2 – 1.0 mm · 0.5 – 1.2 mm · 1.2 – 1.7 mm
Available formats Vial · Syringe
Macropore size 300–400 µm (SEM analysis, published research)
Manufacturer Chiyewon Co., Ltd. — Gyeonggi-do, Korea
Origin Made in Korea
Clinical Tips

Getting the most from Ti-oss®

Practical guidance for predictable grafting outcomes.

1
Match particle size to the defect type. The finer 0.2–1.0mm range suits small extraction sockets and tight defects, while the 1.2–1.7mm range is better suited to larger sinus augmentation and ridge augmentation cases that require greater space maintenance.
2
Hydrate before packing. A few drops of blood, saline, or PRP at the vial or syringe opening allow the multiporous particles to wet through fully before placement — this is part of the intended pore design and supports close contact with the surrounding clot.
3
Choose Vial or Syringe based on surgical access. The Vial format suits open-field grafting where particles are placed and packed directly, such as lateral window sinus grafts, while the Syringe format suits confined or minimally invasive sites where direct, controlled delivery is preferred.
4
Plan healing time around the indication. Published sinus augmentation research evaluated graft maturation at 6–8 months before bone core retrieval; allow a comparable healing window before proceeding to implant placement or second-stage surgery.
5
Combine with a barrier membrane where GBR is indicated. For ridge augmentation or defects requiring protection against soft-tissue ingrowth, Ti-oss® is commonly used alongside a resorbable collagen membrane.
⚠ Clinical Notice: Ti-oss® is a bone graft material derived from BSE-free certified Australian bovine bone, intended for use by trained dental and oral surgical practitioners. Store per manufacturer instructions and do not use if packaging is damaged or sterility is compromised. Refer to the Instructions for Use for full indications, contraindications, and handling guidelines.